Impact of muscarinic agonists for successful therapy of Alzheimer's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 62, 2002, Pages 189-202

  Fisher, A ^a   Brandeis, R ^a   Haring, R ^a   Bar Ner, N ^a   Kliger Spatz, M ^a   Natan, N ^a   Sonego, H ^a   Marcovitch, I ^a   Pittel, Z ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AF 150; AF 267B; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; APOLIPOPROTEIN E; CARBACHOL; CEVIMELINE; DONEPEZIL; GALANTAMINE; GALLIC ACID PROPYL ESTER; HYDROXYCHLOROQUINE; MUSCARINIC AGENT; NICOTINE; OXOTREMORINE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE; TALSACLIDINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; ASTROCYTOSIS; BEHAVIOR DISORDER; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; CONFERENCE PAPER; DRUG EFFECT; DRUG SAFETY; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; AGED; REVIEW;

AGED; ALZHEIMER DISEASE; HUMANS; MUSCARINIC AGONISTS;

EID: 0036047521     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6139-5_18     Document Type: Conference Paper

References (47)

1. Beach TG, Walker DG, Potter PE, Fisher A (2001) Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists. Brain Res 905: 220-223
2. Bons N, Jallageas V, Maestre-Frances N, Silhol S, Petter A, Delacourte A (1995) Microcebus murinus, a convenient laboratory animal for the study of Alzheimer's disease. Alzheimer's Res 1: 83-87
3. Brandeis R, Sapir M, Hafif N, Abraham S, Oz N, Stein E, Fisher A (1995) AF150(S): a new functionally selective M1 agonist improved cognitive performance in rats. Pharmacol Biochem Behav 51: 667-674
4. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, Greengard P (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta-A4 amyloid protein precursor. Proc Natl Acad Sci USA 89: 10075-10078
5. Dineley KT, Westerman M, Bui D, Bell K, Hsiao Ashe K, Sweatt DJ (2001) β-Amyloid activates the mitogen-activated protein kinase cascade via hippocampal α7 nicotinic acetylcholine receptors: in vitro and in vivo mechanism related to Alzheimer's disease. Neurosci 21: 4125-4133
6. Eckols K, Bymaster FP, Mitch CH, Shannon HE, Ward JS, DeLapp NW (1995) The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from CHO M1 cells. Life Sci 57: 1183-1190
7. Farber SA, Nitsch RM, Schulz JG, Wurtman RJ (1995) Regulated secretion of β-amyloid precursor protein in rat brain. J Neurosci 15: 7442-7451
8. Fisher A (1997) Muscarinic agonists for the treatment of Alzheimer's disease: progress and perspectives. Exp Opin Invest Drugs 6: 1395-1141
9. Fisher A (1999) Muscarinic receptor agonists in Alzheimer's disease- more than just symptomatic treatment. CNS Drugs 12: 197-214
10. Fisher A (2000) Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. Jpn J Pharmacol 84: 101-112
11. Fisher A, Haring R, Pittel Z, Brandeis R, Eshhar N, Karton Y, Meshulam H, Lazarovici P, Kushnir M, Heldman E (1998a) Novel therapeutic avenues in Alzheimer's disease based on M1 muscarinic agonists - a unifying concept. Int J Geriatr Psychopharmacol 1: 150-157
12. Fisher A, Brandeis R, Chapman Pittel Z, Michaelson DM (1998b) M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice. J Neurochem 70: 1991-1997
13. Forlenza OV, Spink JM, Dayanandan R, Anderton BH, Olensen OF, Lovestone S (2000) Muscarinic agonists reduce τ phosphorylation in non-neuronal cells via GSK-3β inhibition and in neurons. J Neural Transm 107: 1201-1212
14. Gandy SE, Petanceska S (2000) Regulation of Alzheimer β-amyloid precursor trafficking and metabolism. Biochim Biophys Acta 1502: 44-52
15. Genis I, Fisher A, Michaelson DM (1999) Site-specific dephosphorylation of tau in apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment. J Neurochem 12: 206-213
16. Giannakopoulos P, Silhol S, Jallageas V, Mallet J, Bons N, Bouras C, Delaere P (1997) Quantitative analysis of tau protein-immunoreactive accumulations and beta-amyloid protein deposits in the cerebral cortex of the mouse lemur, Microcebus murinus. Acta Neuropathol 94: 131-139
17. Gurwitz D, Haring R, Pinkas-Kramarski R, Stein R, Heldman E, Karton Y, Fisher A (1995) NGF-dependent neurotrophic-like effects of AF102B, an M1 muscarinic agonist, in PC12M1 cells. NeuroReport 6: 485-488
18. Haring R, Gurwitz D, Barg J, Pinkas-Kramarski R, Heldman E, Pittel Z, Wengier A, Meshulam H, Karton Y, Fisher A (1994) Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist AF102B. Biochem Biophys Res Comm 203: 652-658
19. Haring R, Gurwitz D, Barg J, Pinkas-Kramarsky R, Heldman E, Pittel Z, Danenberg HD, Wengier A, Meshulam H, Marciano D, Karton Y, Fisher A (1995) NGF promotes amyloid protein secretion via muscarinic receptor activation. Biochem Biophys Res Comm 213: 15-23
20. Haring R, Fisher A, Marciano D, Pittel Z, Kloog Y, Zuckerman A, Eshhar N, Heldman E (1998) Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the M1 muscarinic receptor to amyloid precursor protein secretion. J Neurochem 71: 2094-2103
21. 1 muscarinic agonists protect PC12M1 cells from growth factor deprivation and beta-amyloid- induced apoptosis. World Conf on AD, Washington DC, July 9-13
22. Hellstrom-Lindahl E, Moore H, Nordberg A (2000) Increased levels of τ protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J Neurochem 74: 777-784
23. Hock C, Maddalena A, Heuser I, Naber D, Oertel W, von Der Kramer H, Wienrich M, Rachig A, Deng M, Growdon JM, Nitsch RM (2000) Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease. Ann NY Acad Sci 920: 285-291
24. Hung AY, Haass C, Nitsch R, Qiu WQ, Citron M, Wurtman RJ, Growdon JH, Selkoe DJ (1993) Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem 268: 22959-22962
25. Kelly JF, Furukawa K, Barger SW, Rengen MR, Mark RJ, Blanc EM, Roth GS, Matson MP (1996) Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc Natl Acad Sci 96: 6753-6758
26. Ladner CJ, Lee JM (1998) Pharmacological drug treatment of Alzheimer disease: the cholinergic system revisited. J Neuropathol Exp Neurol 57: 719-731
27. Leloup C, Michaelson DM, Fisher A, Hartmann T, Beyreuther K, Stein R (2000) M1 muscarinic receptors blocks caspase activation by phosphatidylinositide 3-kinase and MAPK/ERK-independent pathways. Cell Death Differentiation 7: 825-833
28. Lucas J, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J (2001) Decreased nuclear β-catenin, τ hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J 20: 27-39
29. Mattson MP (1997) Central role of oxyradicals in the mechanism of amyloid β-peptide cytotoxicity. Alzheimers Dis Rev 2: 1-14
30. Muller DM, Mendla K, Farber SA, Nitsch RM (1997) Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci 60: 985-991
31. Nitsch RN, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 58: 304-307
32. Nitsch RM, Deng M, Tennis M, Schoenfield D, Growdon JH (2000) The selective muscarinic M1 agonist AF102B decreases levels of total A (beta) in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 48: 913-918
33. Pavia J, de Ceballos M, de la Cuesta FS (1998) Alzheimer's disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins. Fundam Clin Pharmacol 12: 473-481
34. Perry E, Court J, Goodchild R, Griffiths M, Jaros E, Johnson M, Lloyd S, Piggott M, Spurden D, Ballard C, McKeith I, Perry R (1998) Clinical neurochemistry: developments in dementia research based on brain bank material. J Neural Transm 105: 915-933
35. Pittel Z, Heldman E, Barg J, Haring R, Fisher A (1996) Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. Brain Res 742: 299-304
36. Pittel Z, Haring R, Natan N, Marcovitch I, Fisher A (2000) Aβ impair M1 muscarinic receptor-mediated signaling yet Aβ-induced cell death is attenuated by M1 agonists. Soc Neurosci Abstr 663.17
37. Ruske AC, White KG (1999) Facilitation of memory performance by a novel muscarinic agonist in young and old rats. Pharmacol Biochem Behav 63: 663-667
38. Ruske AC, Fisher A, White KG (1997) Attenuation of scopolamine-induced deficits in delayed-matching to performance of a new muscarinic agonist. Psychobiol 25: 313-320
39. Sadot E, Gurwitz D, Barg J, Behar L, Ginzburg I, Fisher A (1996) Activation of m1-muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J Neurochem 66: 877-880
40. 1 subtype selective muscarinic agonists for Alzheimer's disease: translation of in vitro selectivity into in vivo efficacy. Drug Dev Res 40: 133-143
41. Silhol S, Calenda A, Jallageas V, Maestre-Frances N, Bellis M, Bons N (1996) Beta-amyloid protein precursor in Microcebus murinus: genotyping and brain localization. Neurobiol Dis 3: 169-182
42. Small DH, Mok SS, Bornstein J (2001) Alzheimer's disease and A-beta toxicity: from top to bottom. Nature Rev 2: 595-698
43. Svensson AL, Alafuzoff I, Nordberg A (1992) Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. Brain Res 596: 142-148
44. 1 agonist, enhanced spatial learning in C57BL/10 mice with a long duration of action. Brain Res 597: 264-268
45. Wolf BA, Wertkin AM, Jolly YC, Yasuda RO, Wolfe BB, Konrad RJ, Manning D, Ravi S, Williamson JR, VM-Y Lee (1995) Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J Biol Chem 270: 4916-4922
46. Wolfe MS (2001) Secretase targets for Alzheimer's disease: identification and therapeutic potential. J Med Chem 44: 2039-2060
47. Yan X-Z, Xiao R, Dou Y, Wang S-D, Qiao Z-D, Qiao J-T (2000) Carbachol blocks beta-amyloid fragment 31-35-induced apoptosis in cultured cortical neurons. Brain Res Bull 51: 465-470